Marker Therapeutics (NASDAQ:MRKR) released its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.16), MarketWatch Earnings reports.
Shares of MRKR traded down $0.08 on Thursday, hitting $2.08. 3,204,905 shares of the stock traded hands, compared to its average volume of 2,874,790. The company has a market capitalization of $164.95 million, a PE ratio of -4.04 and a beta of 1.27. The business has a 50 day simple moving average of $2.28 and a 200 day simple moving average of $2.01. Marker Therapeutics has a one year low of $1.32 and a one year high of $3.77.
In other news, Director John Robert Wilson purchased 1,714,285 shares of Marker Therapeutics stock in a transaction that occurred on Tuesday, March 16th. The stock was bought at an average price of $1.75 per share, with a total value of $2,999,998.75. Following the completion of the transaction, the director now directly owns 7,799,350 shares of the company’s stock, valued at $13,648,862.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Peter L. Hoang purchased 142,857 shares of Marker Therapeutics stock in a transaction that occurred on Tuesday, March 16th. The shares were purchased at an average cost of $1.75 per share, with a total value of $249,999.75. Following the transaction, the chief executive officer now directly owns 332,568 shares of the company’s stock, valued at $581,994. The disclosure for this purchase can be found here. Insiders have purchased 8,142,855 shares of company stock valued at $14,249,996 in the last three months. 30.90% of the stock is owned by insiders.
About Marker Therapeutics
Marker Therapeutics, Inc, a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
Featured Story: Outperform Rating
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.